driver-mutations
(2)
Clasp Therapeutics
Clasp Therapeutics is a clinical-stage immuno-oncology company building off-the-shelf, antibody-like T cell engagers that target cancer driver mutations presented on tumor cells via HLA. Spun out of Johns Hopkins and co-founded by cancer-genetics pioneer Bert Vogelstein and immunotherapy leader Drew Pardoll, Clasp uses its proprietary pHLAre platform to redirect a patient's own T cells to kill tumors with what the company calls absolute specificity - hitting mutant peptides found only on cancer cells while sparing healthy tissue. The company launched publicly in March 2024 with a $150 million Series A and dosed its first patient in April 2025.
Darrin Miles
Darrin Miles is the President and CEO of Nested Therapeutics, a Cambridge, Massachusetts precision oncology company that launched in 2022 with $125 million in financing to hunt for cancer-driving mutations hiding in plain sight. A commercialization leader with more than two decades in healthcare, Miles spent 14 years at Genentech shepherding landmark cancer brands and later served as Chief Commercial Officer at Agios Pharmaceuticals, where he helped bring the first mutant-IDH therapies to acute myeloid leukemia patients. At Nested, he is translating computational biophysics, genomics, and chemical biology into drugs aimed at targets the rest of the field calls undruggable.